Unexpected Pleural Effusions in 3 Pediatric Patients Treated With STI-571

Goldsby, Robert E.; Pulsipher, Mike A.; Adams, Roberta H.; Coffin, Cheryl M.; Albritton, Karen; Wagner, Lars M.

doi:10.1097/00043426-200211000-00020

Cited by 31 publications

(10 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…35,36 In addition to peripheral and facial edema, therapy has been associated with pleural and pericardial effusions. 35,37,38 Coleman et al reported edema in 14% of patients and ascites in 10% of patients (grade 3 in 2 of 3 patients). New-onset ascites in ovarian cancer generally is interpreted as disease progression.…”

Section: Discussionmentioning

confidence: 99%

A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer

Posadas

Kwitkowski²,

Kotz³

et al. 2007

Cancer

View full text Add to dashboard Cite

The morphology of the telencephalon displays great diversity among different vertebrate lineages. Particularly the everted telencephalon of ray‐finned fishes shows a noticeably different morphology from the evaginated telencephalon of nonray‐finned fishes and other vertebrates. This makes the comparison between the different parts of the telencephalon of ray‐finned fishes and other vertebrates difficult. Based on neuroanatomical, neurochemical, and connectional data no consensus on the subdivisions of the adult telencephalon of ray‐finned fishes and their relation to nuclei in the telencephalon of other vertebrates has been reached yet. For tetrapods, comparative expression pattern analysis of homologous developmental genes has been a successful approach to clarify homologies between different parts of the telencephalon. In the larval zebrafish, subdivisions of the subpallium have been proposed using conserved developmental gene expression. In this study, we investigate the subdivisions of the adult zebrafish telencephalon by analyzing the expression pattern of conserved molecular marker genes. We identify the boundary between the pallium and subpallium based on the complementary expression of dlx2a, dlx5a in the subpallium and tbr1, neurod in the pallium. Furthermore, combinatorial expression of Isl, nkx2.1b, lhx1b, tbr1, eomesa, emx1, emx2, and emx3 identifies striatal‐like, pallidal‐like, and septal‐like subdivisions within the subpallium. In contrast to previous models, we propose that the striatum and pallidum are stretched along the rostrocaudal axis of the telencephalon. Further, the septal nuclei derive from both the pallium and subpallium. On this basis, we present a new model for the subdivisions of the subpallium in teleost fish. J. Comp. Neurol. 520:633–655, 2012. © 2011 Wiley Periodicals, Inc.

show abstract

Section: Discussionmentioning

confidence: 99%

A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer

Posadas

Kwitkowski²,

Kotz³

et al. 2007

Cancer

View full text Add to dashboard Cite

show abstract

“…There were 479 total courses (28 consecutive days) of imatinib in doses of 260–570 mg/m 2 /day and the frequency of non‐hematologic adverse events is given in Table I. The great majority were grade 1 or 2, although the occasional occurrence of considerable fluid retention has been reported by others 59. No effort was made to define a maximum tolerated dose because of the high response rate at doses of imatinib comparable to or greater than those used routinely in adults: all patients (n = 14) with chronic phase CML had complete hematologic responses and 83% (12/14) had a cytogenetic complete remission.…”

Section: Evidence From Clinical Experiencementioning

confidence: 99%

Updated clinical practice guidelines for the prevention and treatment of mucositis

Keefe

Schubert

Elting

et al. 2007

Cancer

704

430

View full text Add to dashboard Cite

The opinions or views expressed in this professional review are those of the authors and do not necessarily reflect the opinions or recommendations of the publisher or the companies that provided grants toward this process. This article is being published with the full knowledge and consent of the authors. This article may discuss pharmaceutical products and/or uses of products that have not been approved by the U.S. Food and Drug Administration or other regulatory authorities outside of the United States. For approved product information, consult the manufacturer's prescribing information or the applicable regulatory authority. Dosages, indications, and methods of use for compounds that are referred to in this article may be derived from the professional literature or other sources. In vitro and animal data may not correlate with clinical results and do not demonstrate clinical safety or efficacy in humans.We acknowledge the assistance of Lee Ann Chastain in the preparation of this article.

show abstract

“…22 The negligible effects of imatinib on PDGFRB may explain the low incidence of this event with this agent. [23][24][25] Another possible explanation is that tyrosine kinases responsible for capillary integrity may be overexpressed in the pulmonary vasculature and/or pleural epithelium. Src regulates focal adhesion and adherens junctions, two subcellular matrix attachment structures key in regulating cell adhesion, 26,27 which may play a role in the stability of the pleural epithelium and pleural space homeostasis.…”

mentioning

confidence: 99%

Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia

Kojima

Nakamura

Amaki

et al. 2017

J Clin Exp Hematopathol

View full text Add to dashboard Cite

JC EH lin xp ematopathol Case Study INTRODUCTIONChronic myelogenous leukemia (CML) is a chronic myeloproliferative neoplasm that originates from multipotent hematopoietic stem cells and is associated with the BCR-ABL fusion gene located on the Philadelphia (Ph) chromosome.1 Based on historical data prior to any effective therapy, median survival times for CML ranged between 2 and 3 years. 2 However, in the current era of tyrosine kinase inhibitor (TKI) therapy using imatinib, dasatinib, nilotinib, and bosutinib, the prognosis has been markedly improved. 3 Currently, an important issue is the management of adverse events. Pleural effusion is one of the major problems. The TKIs have different patterns of side effects, and pleural effusion is more frequently observed with dasatinib compared with imatinib, nilotinib, and bosutinib. [4][5][6][7] Primary effusion lymphoma (PEL) is a rare type of nonHodgkin lymphoma (NHL) confined to the body cavities, usually without a tumor mass.1 It is associated with infection of human herpesvirus 8 (HHV-8), and Epstein-Barr virus (EBV) coinfection is common, especially with a background of human immunodeficiency virus type-1 (HIV) infection. 8 However, some cases of HHV-8-negative primary lymphomatous effusion have been reported and termed HHV-8-unrelated PEL-like lymphoma. 9,10 In this report, we present a rare case of PEL-like lymphoma that was found during pleural effusion treatment with TKIs for CML. CASE REPORTA 69-year-old Japanese male was hospitalized for cerebral infarction. Peripheral blood evaluation revealed a hemoglobin level of 12.2 g/dl, a platelet count of 98.6 x 10⁴ / μl, a white blood cell count of 26,800 /μl with 86% neutrophils, 6% lymphocytes, 1% monocytes, 1% eosinophils, 2% basophils, 2% myelocytes, and 2% metamyelocytes. Hepatitis B, Hepatitis C, HIV, and HTLV-1 were negative. Hypercellular bone marrow with an increase of megakaryocytes was observed on the bone marrow test, and the myeloblast count was less than 5% (Figure1). Chromosomal analysis was abnormal with 46, XY, t(9;22)(q34;q11.2) [20/20]. The patient was diagnosed with CML in the chronic phase. Dasatinib was started at 100 mg once daily. After a year of dasatinib treatment, the patient achieved major molecular response (MMR). However, he developed dyspnea and bilateral pleural effusion was observed on chest X-ray; therefore, diuretics were started. After two years on dasatinib, the patient achieved complete molecular response (CMR), but dasatinib treatment was discontinued due to exacerbation of Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia A 69-year-old man was diagnosed with chronic myelogenous leukemia (CML) and treated with dasatinib. After two years on dasatinib, the patient achieved complete molecular response, but dasatinib treatment was discontinued due to exacerbation of pleural effusion. Nilotinib and imatinib were started but stopped due to an increase in pleural effusion. Thoracentes...

show abstract

Unexpected Pleural Effusions in 3 Pediatric Patients Treated With STI-571

Cited by 31 publications

References 4 publications

A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer

A prospective analysis of imatinib‐induced c‐kit modulation in ovarian cancer

Updated clinical practice guidelines for the prevention and treatment of mucositis

Human herpesvirus 8-unrelated primary effusion lymphoma-like lymphoma following tyrosine kinase inhibitor treatment for chronic myelogenous leukemia

Contact Info

Product

Resources

About